Search Results - "Cotarla, I"

Understanding breast cancer risk ‐ where do we stand in 2005? by Dumitrescu, R. G., Cotarla, I.

“…Breast cancer is the most frequent cancer in women and represents the second leading cause of cancer death among women (after lung cancer). The etiology of…”
Get full text

A Prospective, Multi-Institutional Digital Health Pilot Study to Detect Pneumonitis Early in Patients with Stage III NSCLC on durvalumab Monitored Remotely: Findings from the ON TRAX Study by Cotarla, I., Saltos, A.N., Peikert, T.D., Tannenwald, B., Hsieh, K., Irabor, O.C., Frankart, A.J., Bhosale, A., Zahradka, N., Wilkes, M., Gray, J.

Get full text

409 POSTER A Phase I clinical trial of the oral PPAR gamma agonist, CS-7017 in patients with advanced malignancies by Pishvaian, M.J, Wagner, A, Deeken, J, He, A.R, Hwang, J, Malik, S, Cotarla, I, Demetri, G, Marshall, J.L, Wojtowicz-Praga, S

Get full text

Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment by Yong, Candice, Cambron-Mellott, M Janelle, Seal, Brian, Will, Oliver, Maculaitis, Martine C, Clapp, Kelly, Mulvihill, Emily, Cotarla, Ion, Mehra, Ranee

“…The approval of immune checkpoint inhibitors for metastatic non-small-cell lung carcinomas (mNSCLC) treatment has presented more care options. Therefore, it is…”
Get full text

Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers by Cotarla, Ion, Ren, Shuxun, Zhang, Ying, Gehan, Edmund, Singh, Baljit, Furth, Priscilla A.

“…Signal transducers and activators of transcription (STATs) are latent cytoplasmic transcription factors that are activated and translocated into the nucleus…”
Get full text

Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies by Pishvaian, M. J., Cotarla, I., Wagner, A. J., Deeken, J. F., He, A. R., Hwang, J. J., Demetri, G. D., Halim, A., Copigneaux, C., Marshall, J.

“…Abstract only…”
Get full text

A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion by Pishvaian, M. J., Marshall, J. L., Hwang, J. J., Malik, S., He, A. R., Deeken, J. F., Kelso, C. B., Cotarla, I., Berger, M. S.

“…Abstract only 3581 Background: GMX1777 is a pro-drug which converts to GMX1778, a potent and specific small molecule inhibitor of NAMPRT, the rate-limiting…”
Get full text

Conditional over-expression of estrogen receptor alpha in a transgenic mouse model by HRUSKA, Kathleen S, TILLI, Maddalena T, FLAWS, Jodi A, SHUXUN REN, COTARLA, Ion, KWONG, Theresea, MINGLIN LI, FONDELL, Joseph D, HEWITT, Judy A, KOOS, Robert D, FURTH, Priscilla A

“…Attempts to delineate the mechanisms of estrogen action have promoted the creation of several estrogen receptor alpha (ERalpha) mouse models in the past…”
Get full text